Condition: Non-small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC) · Pancreatic Adenocarcinoma · Sponsor: Revolution Medicines, Inc.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
This description comes directly from the study's public registry record.
Revolution Medicines Study Director · 1-844-2-REVMED · medinfo@revmed.com
Always discuss trial participation with your own doctor first.
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone Health | New York, New York, United States | Recruiting |
| NEXT - Dallas | Dallas, Texas, United States | Recruiting |
| NEXT | San Antonio, Texas, United States | Recruiting |
| START - San Antonio | San Antonio, Texas, United States | Recruiting |
| NEXT - Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07349537